Price · last 3 months · daily close
COO price
Loading the price chart...
Daily closing prices via yfinance. Quotes are delayed. Past prices are not a guarantee of future results.
ValeriusBeta - Not investment advice
Research · S&P 500 · Health Care
The numbers, the scorecard and what analysts say, with the source for each. Information, not advice.
Price · last 3 months · daily close
Loading the price chart...
Daily closing prices via yfinance. Quotes are delayed. Past prices are not a guarantee of future results.
Value Scorecard · run 2026-10-18
Earnings & returns
Diluted EPS: $1.94 (2022), $1.48 (2023), $1.96 (2024), $1.87 (2025). It ended at or below 2022; the framework scores that as 2.
ROE (net income / common equity): 5.4% (2022), 3.9% (2023), 4.9% (2024), 4.6% (2025). Median 4.7%, lowest 3.9%; the framework scores a median 5% or less as 1.
ROIC of 6.1%: operating income of $682.90M divided by $11.28B of capital (total assets $12.39B minus current liabilities $1.11B), fiscal year to Oct 31, 2025, as filed in the 10-K (SEC EDGAR). The framework scores 5-10% as 2.
Net margin of 13.5%; the framework scores 10-20% as 4; gross margin 65.9%, operating margin 20.8%.
Balance sheet & cash
Debt-to-equity of 0.34; the framework scores 0.3-0.8 as 4 (total debt $2.80B, total cash $154.70M).
Free cash flow (operating cash flow minus capital expenditure): $450.40M (2022), $215.00M (2023), $288.10M (2024), $433.70M (2025). It ended at or below 2022; the framework scores that as 2.
Retained earnings, as filed in the 10-Ks (SEC EDGAR): $6.58B (2022), $6.88B (2023), $7.27B (2024), $7.64B (2025). It rose every year; the framework scores that as 5.
Valuation models
IV = EPS x (8.5 + 2g) x (4.4 / Y) = $2.91 x (8.5 + 2 x 12.5) x (4.4 / 4.5) = $95.32. Current price $57.94; price is 39.2% below the model value.
FCF/share = $2.854, stage 1 growth = 6.7% for 5 years, terminal growth = 3%, discount rate = 10%. Stage 1 PV = $13.03, PV of terminal value = $36.06, DCF value = $49.09. Current price $57.94; price is 18.0% above the model value.
Graham value $95.32 (price is 39.2% below the model value); DCF value $49.09 (price is 18.0% above the model value).
P/B of 1.32; the framework scores 1.0-1.5 as 4.
Business quality
A moat (a brand, a network, switching costs, patents, scale, a licence) is not a number in the filings, so Valerius doesn’t score it. Below are the figures and the words moat analysis starts from, from the company’s own 10-K filings. The conclusion is yours.
Return on capital, each year
Above 15% in 0 of 10 years (2016-2025); lowest 5.0%, highest 10.6%.
Gross margin, each year
Between 59.6% and 66.9% over 10 years (a range of 7.3 points).
Competition, in the company’s own words · 10-K filed Dec 5, 2025
The markets in which we participate are highly competitive and involve the continual search for technological and scientific innovations. Competitive factors in these markets include technological and scientific advances, product quality and availability, price, customer service including response time and effective communication of product information to clinicians and consumers, and manufacturing processes. Competitors may have greater financial resources, larger research and development budgets, larger sales forces, greater market penetration and/or larger manufacturing capacity. Both CooperVision and CooperSurgical compete predominantly on the basis of product quality and differentiation, technological benefits, price, service levels and reliability.
The opening of the company’s “COMPETITION” section in its 10-K, quoted word for word, not summarized or edited. It is the company’s own description, not Valerius’s view, and may include the company’s expectations. Open the filing.
Return on capital = operating income / (total assets − current liabilities), the ROIC row’s definition; 15% is the framework’s return threshold. Gross margin = gross profit / revenue. Both from each year’s 10-K via SEC EDGAR. Moat analysis commonly looks at whether returns and margins held up over many years. These figures don’t say whether the company has an advantage, what it is, or whether it will last.
Capital allocation, 2022-2025: dividends or buybacks paid in 3 of 4 years (fail); $374.60M paid out against $1.39B of free cash flow (pass); total debt $2.76B to $2.51B, down 9.3%, 2.4x EBITDA (pass: not up more than 10%); shares outstanding 0.20B to 0.20B, down 0.7% (pass). 3 of 4 tests passed; the framework scores that as 4.
Filings
Three kinds of event the company reported to the SEC in the last 5 years, from its filings on SEC EDGAR.
Loading...
These are events the company reported to the SEC. An auditor change or a late filing can have many causes; each date links to the filing, where the company explains it. Valerius does not score these.
Graham Formula:
IV = EPS x (8.5 + 2g) x (4.4 / Y)
EPS = $2.91, g = 12.5%, Y = 4.5
IV = $95.32
Current price $57.94 vs Graham value $95.32 — price is 39.2% below the model value.
DCF:
FCF/share = $2.854
Stage 1 growth = 6.7% for 5 years | terminal growth = 3.0% | discount rate = 10.0%
Y1: $3.045 → PV $2.768
Y2: $3.249 → PV $2.685
Y3: $3.467 → PV $2.605
Y4: $3.699 → PV $2.526
Y5: $3.947 → PV $2.451
Stage 1 PV sum = $13.03
Terminal value at end of Y5 = $58.07
PV of terminal value = $36.06
DCF value = $49.09
Current price $57.94 vs DCF value $49.09 — price is 18.0% above the model value.Data from yfinance summary figures and financial statements, and from the company’s 10-K filings via SEC EDGAR; computed at a price of $57.94. Every score is calculated from the figures by the framework’s fixed rules, and the explanation beside it is generated from the same figures: Graham value, DCF value, margin of safety, ROIC, profit margins, debt-to-equity, price-to-book, EPS trend, ROE trend, free cash flow, retained earnings and capital allocation. No AI is involved in this scorecard. The moat is shown as evidence, without a score. Read each score with the figures beside it. Intrinsic value calculations are model outputs based on stated assumptions, not predictions.
Recent headlines · third-party publishers · not investment advice
The 8 newest headlines whose title names the company, shown automatically and never chosen by Valerius. From third-party publishers via Yahoo Finance, linked to the source. Valerius doesn't write or endorse them. Not investment advice.